260 results about "AD - Atopic dermatitis" patented technology

The invention relates to a novel application of animal bifidobacterium subsp. Lactis BGI-N3, in particular to an application of the animal bifidobacterium subsp. Lactis BGI-N3 in preparation of a preparation for relieving skin allergy. The invention finds that the bifidobacterium animalis subsp. Lactis BGI-N3 has a very remarkable effect in the aspect of relieving skin allergy, and the effect is specifically shown as follows: in an atopic dermatitis animal model, the dermatitis score, scratching times and percutaneous water loss are remarkably reduced, and the atopic dermatitis skin tissue damage condition is relieved; the immune organ edema condition is improved, the levels of Th2 type cell factors and inflammatory factors IL-6, TNF-alpha and IFN-gamma related to dermatitis are reduced, and the immune balance of the body is recovered; expression of fibroin and endothelial protein in skin tissue is improved, and the skin barrier is repaired; the level of antibacterial peptide in skin tissues is recovered, and the antibacterial activity of the skin is enhanced. Meanwhile, compared with a traditional chemical medicine for treating atopic dermatitis, the animal bifidobacterium subsp. Lactis BGI-N3 has no side effects such as weight loss, immune organ atrophy, immune imbalance and the like.

The invention discloses a novel application of bifidobacterium longum subsp. Infantis CCFM1269 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium longum subsp. Infantis CCFM1269 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mast cell infiltration is reduced; (2) reducing the total IgE level of serum; (3) the Treg level of mesenteric lymph nodes and the ILA content of serum are improved; (4) IL-4 and TSLP levels in skin tissues are reduced, IL-10 is improved, and Th1 / Th2 immune balance is recovered; (5) improving AHR and CYP1A1 in the skin tissue; and (4) high yield of ILA.

The invention discloses application of a zingiber mioga extract in preparation of a medicine for treating atopic dermatitis, and belongs to the technical field of medicines.The zingiber mioga extract is specifically a zingiber mioga rhizome aqueous extract, can act on all stages of atopic dermatitis to achieve the purposes of relieving inflammation and improving itching symptoms, has higher safety and effectiveness, and can be used for preparing a medicine for treating atopic dermatitis. Therefore, the traditional Chinese medicine composition has great potential and unique advantages in the aspect of treating atopic dermatitis. The invention provides a new thought for developing the atopic dermatitis medicine, and also expands the application direction of the zingiber mioga.

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

The invention provides systems and methods for diagnosing and treating an inflammatory skin disease in a patient. The described methods may be used for longitudinal monitoring of the development, progression, or regression of a skin disease including lupus, psoriasis, atopic dermatitis, and systemic sclerosis (scleroderma) condition in a patient, in response to a therapy administered for the condition.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention discloses a hydrogel dressing for treating atopic dermatitis and a preparation method and application thereof, and belongs to the technical field of skin medical materials. The dressing is prepared by taking a glycerol / water / ethanol ternary mixed solvent as a dissolving system, dissolving polyvinyl alcohol, tannic acid and aluminum trichloride to construct a polymer skeleton matrix, and then adding traditional Chinese medicine active ingredients. The preparation does not need complex temperature control curing, the ternary solvent can realize uniform dissolution and stable dispersion of the active ingredients, the effective ingredients are prevented from being damaged by high temperature, the encapsulation efficiency of the traditional Chinese medicine extract is more than 90%, and the medicine can be slowly released for 72 hours. The dressing has a multi-target anti-inflammatory effect, can reduce the level of TNF-alpha at a skin lesion and promote proliferation of keratinocytes, is excellent in tensile and torsional stability, and can be attached to the skin for a long time in a dynamic environment. The preparation method is simple in process, controllable in raw material cost, high in production efficiency, suitable for large-scale production, good in dressing biocompatibility, high in safety, suitable for treatment of atopic dermatitis of different severity degrees and large in clinical transformation potential.

The invention belongs to the technical field of microorganisms, and discloses a bifidobacterium animalis subsp. Lactis XB02 strain capable of inhibiting pathogenic bacteria and improving inflammation, the preservation number of the bifidobacterium animalis subsp. Lactis XB02 strain is CGMCC (China General Microbiological Culture Collection Center) No.34942, and the preservation date is June 18, 2025. Meanwhile, the probiotic composition adopting the bacterial strain XB02 also comprises a lactobacillus rhamnosus XB01 bacterial strain. The XB02 strain disclosed by the invention has excellent bacteriostatic activity, especially for vibrio parahaemolyticus and gardneria; the atopic dermatitis symptom can be obviously improved; the intestinal mucosa permeability is reduced, and the intestinal barrier function is enhanced; and when the strain is combined with the XB01 strain for use, a synergistic sleep promoting effect is shown. The invention further provides a probiotic composition containing the strain, a preparation and application of the probiotic composition and the preparation in food, medicine or health care products.

Methods are provided for treating moderate to severe atopic dermatitis of the hands and / or feet in a subject. In one aspect, the methods include administering to the subject one or more doses of an interleukin-4 receptor (anti-IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

The application provides a drying method of Chuanxiong medicinal material and application of Chuanxiong or its extract in preparation of an external medicine for treating atopic dermatitis. The drying method of Chuanxiong medicinal material improves Chuanxiong processing efficiency, shortens processing period, obtains by-product Chuanxiong extract in addition to preparation of decoction pieces, reduces energy consumption and lowers production cost. The Chuanxiong essential oil and Chuanxiong extract are both composed of small molecule components, have good affinity to skin, are absorbed through skin quickly, can quickly relieve symptoms such as itching and skin damage caused by atopic dermatitis, and are natural, safe and free of side effects. Meanwhile, the small molecule components contained in the Chuanxiong essential oil and Chuanxiong extract have good lipophilicity, have softening effect on the thickened stratum corneum caused by atopic dermatitis, and are more conducive to drug absorption. In addition, the Chuanxiong essential oil and Chuanxiong extract are simple to prepare and low in price.

The invention belongs to the technical field of skin disease treatment and medicine, and particularly relates to an external pharmaceutical composition for treating atopic dermatitis and a preparation method and application thereof. The medicine composition is liquid medicine composed of blumea balsamifera oil, perfoliote knotweed herb and piper cubeba extract and is specially used for treating the atopic dermatitis (AD). According to the composition, the blumea balsamifera oil is innovatively used as a main component and cooperates with the perfoliote knotweed herb and the piper cubeba extract to form an efficient treatment scheme, and the curative effect of the composition is remarkably superior to that of a traditional method for singly using the blumea balsamifera oil. Experiments prove that the composition can effectively improve the skin barrier function, regulate immune disorder, reduce the levels of serum IgE and TSLP and inflammatory factors IL-4 and IFN-gamma, and reduce inflammatory cell infiltration, so that the AD symptom is relieved, and the recurrence rate is reduced.

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

The application belongs to the technical field of medicine or cosmetics, and particularly relates to a composition for treating atopic dermatitis and application thereof. The composition is composed of polysaccharide of Arnebia euchroma and naphthoquinone of Arnebia euchroma, and the mass ratio of the polysaccharide of Arnebia euchroma to the naphthoquinone of Arnebia euchroma is 250-500:1. The polysaccharide of Arnebia euchroma and the naphthoquinone of Arnebia euchroma are compounded according to a specific ratio, and the two components have a synergistic effect, can significantly inhibit secretion of inflammatory factors, and promote expression of key proteins of a skin barrier, so that atopic dermatitis is treated from two paths of 'anti-inflammation' and 'barrier repair', and the effect is significantly better than that of a single component. The composition of the application is derived from natural plant ingredients, has high safety, can be prepared into various dosage forms, is used for auxiliary treatment or daily care of atopic dermatitis, and has a good application prospect.

This invention discloses a Litsea cubeba extract, its preparation method, and its applications, relating to the field of pharmaceutical compound technology. The Litsea cubeba extract has the structural formula shown in Formula I: (Formula I). ​​This Litsea cubeba extract is isolated from the Litsea cubeba plant. This novel compound can significantly inhibit NO production in an LPS-induced RAW264.7 cell inflammation model; alleviate the immune-inflammatory response in an in vitro 3D skin model of atopic dermatitis; inhibit epidermal thickening and repair skin barrier function; and reduce the inflammatory response by inhibiting the PI3K / Akt signaling pathway. It has clinical application potential in the treatment of atopic dermatitis and can be used to prepare anti-atopic dermatitis drugs, showing promising application prospects.

The application discloses application of a human lactoferricin peptide in anti-inflammatory soothing and skin barrier repair. The application relates to the field of biotechnology, and provides application of a polypeptide or a biological material related to the polypeptide in preparation of a product with anti-inflammatory soothing and / or skin barrier repair functions; the polypeptide is a human lactoferricin peptide derived from a filtrate of a yeast fermentation lysate product, and an amino acid sequence of the polypeptide is shown as SEQ ID NO:1. The polypeptide has intervention potential on inflammation related to dermatitis and eczema, especially on atopic dermatitis. The polypeptide can be applied to the fields of medicines and cosmetics.

The application discloses application of 12-ketolithocholic acid in preparation of a medicine for preventing or treating atopic dermatitis, and the 12-ketolithocholic acid can inhibit NUAK2 kinase activity expression and activity, and then negatively regulates a downstream TNF inflammatory signal path, significantly down-regulates IL-1beta, IL-8 and various proinflammatory factor secretion, and inhibits keratinocyte excessive inflammatory activation. The 12-ketolithocholic acid and ginsenoside F2 are compounded and used in combination to produce synergistic effect, and the anti-inflammatory effect is further enhanced; the active substance has low cytotoxicity and good safety, can be prepared into an external ointment or an oral preparation, and has a wide application prospect in the field of atopic dermatitis prevention and treatment.

Provided are methods of diagnosis and treatment of atopic dermatitis.

The application relates to the technical field of medical materials, and discloses a functionalized hydrogel for treating atopic dermatitis and a preparation method and application thereof, the preparation method comprising the following steps: taking g-C3N4 powder as raw material to prepare C3N4 gel with a three-dimensional network structure; taking g-C3N4 powder and CDs powder as raw material, adding a matrix solution, and uniformly ultrasonically dispersing; adding a crosslinking agent solution to make the solution fully undergo crosslinking reaction to prepare a CDs / g-C3N4 crosslinking solution; pouring the above-mentioned CDs / g-C3N4 crosslinking solution into the above-mentioned C3N4 gel, standing for gelation, forming a functionalized modified carbon nitride gel three-dimensional network structure, and freeze-drying to obtain a functionalized three-dimensional crosslinking hydrogel. The functionalized three-dimensional crosslinking hydrogel prepared by the application has the advantages of degradability and the ability to penetrate through an intact skin barrier; and can be used for treating atopic dermatitis.

The application discloses a Qingjiang Aurantii Fructus extract with soothing and repairing effects on atopic dermatitis and application thereof, and a preparation method of the Qingjiang Aurantii Fructus extract comprises the following steps: A1, crushing Qingjiang Aurantii Fructus, adding water to soak, and then sterilizing; A2, inoculating probiotics in the solution after sterilization in step A1 to perform fermentation; A3, filtering the obtained fermentation liquor after sterilization, and purifying to obtain the Qingjiang Aurantii Fructus extract; wherein the probiotics are at least one selected from lactic acid bacteria, bacillus and yeast fungi. The Qingjiang Aurantii Fructus extract obtained by fermenting Qingjiang Aurantii Fructus with specific probiotics has significant soothing, repairing and anti-inflammatory effects, and has the soothing and repairing effects on atopic dermatitis in particular.

The invention relates to the field of medicine, more specifically to treatment of a condition associated with CD4+ T cell-mediated overactivation of the immune system.

The application belongs to the technical field of medicines, and specifically provides application of Phanginin A in preparation of medicines for preventing and / or treating skin diseases. The skin diseases include atopic dermatitis and skin epidermal barrier damage. The application finds that Phanginin A can reduce atopic dermatitis lesion scores, improve atopic dermatitis skin pathological thickening and inflammatory cell infiltration, reduce spleen inflammatory response, inhibit volume increase, promote thymus function recovery, down-regulate expression of atopic dermatitis related inflammatory factors IL-6 and TNF-alpha, and can be used for preventing and / or treating atopic dermatitis. In addition, the application also finds that Phanginin A can promote keratinocyte scratch healing, and can be used for repairing skin epidermal barrier damage.

Compounds, compositions, and methods are provided for treating atopic dermatitis (AD) in patients in need.

The invention provides a marker composition for evaluating the atopic dermatitis treatment effect of mesenchymal stem cells and application of the marker composition, and relates to the technical field of biology. The marker composition is prepared from an Ighg1 gene, an Mfsd4a gene and a Selenbp1 gene. The marker composition is applied to preparation of a product for evaluating the atopic dermatitis treatment effect of a subject treated by the mesenchymal stem cells, and the problem that in the prior art, a method for evaluating the atopic dermatitis treatment effect of the mesenchymal stem cells is lacked is solved.

The invention relates to a tetrapeptide of formula N-Palmitoyl-Lys-Thr-Phe-Lys, for use in the prevention and / or treatment of human atopic dermatitis (AD), as well as to a composition comprising at least said tetrapeptide and at least one physiologically acceptable excipient, for use in the prevention and / or treatment of human atopic dermatitis (AD).

The disclosure relates to pharmaceutical formulations and method of using chymase inhibitors for the prevention and treatment of mast cell-related disease states in which chymase is involved. More particularly the present disclosure is in the field of treating or preventing or reducing the symptoms of mast cell-related diseases, including atopic dermatitis (AD), chronic urticaria (CU), Eosinophilic Gastrointestinal Disorders (EGIDs), and prurigo nodularis (PN), using a chymase inhibitor, including a chymase inhibitor that prevents cleavage of stem cell factor (SCF) and its interaction with receptor tyrosine kinase (c-kit), thereby reducing mast cell activation and proliferation.

The present invention provides an apparatus for managing atopic dermatitis based on a learning model and a method therefor. The method for managing atopic dermatitis according to the present invention includes the steps of: collecting, basic data including a patient's daily life factor, biometric factor, mental health factor, skin status factor, weather-related environmental factor, and an atopic dermatitis severity index based on the medical record; learning a weight for each detailed variable by applying, to a learning model, the relationship between the atopic dermatitis severity index and respective detailed variables for a plurality of factors; determining a reference value of the weight for selecting, as valid variables, N detailed variables for each factor; reconstructing the learning model by selecting, for each factor, N valid variables; and predicting the atopic dermatitis severity index by applying, to the reconstructed learning model, the currently corrected basic data of the patient to be analyzed.

The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.

Provided are compounds, compositions and methods for treating atopic dermatitis (AD) in patients in need thereof.